服务热线
15339069646服务热线
15339069646| Item | Cat. No. | Application | Isotype |
| Anti-CLU mAbs [Sotevtamab Biosimilar] (MABL-5251) | MABL-5251 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-SARS-CoV-2 Spike RBD mAbs [Sotrovimab Biosimilar] (MABL-5252) | MABL-5252 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-CTLA4/CD152 mAbs [Sovipostobart Biosimilar] (MABL-5253) | MABL-5253 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDCD1/CD279/PD1 mAbs [Spartalizumab Biosimilar] (MABL-5254) | MABL-5254 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-IL36RN mAbs [Spesolimab Biosimilar] (MABL-5255) | MABL-5255 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IAP/CD47;CLDN18 mAbs [Spevatamig Biosimilar] (MABL-5256) | MABL-5256 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa |
| Anti-MSTN/GDF8/GDF-8/GDF8 mAbs [Stamulumab Biosimilar] (MABL-5257) | MABL-5257 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-IL4R/CD124 mAbs [Stapokibart Biosimilar] (MABL-5258) | MABL-5258 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-SIGLEC2/CD22 mAbs [Suciraslimab Biosimilar] (MABL-5259) | MABL-5259 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDL1/CD274 mAbs [Sudubrilimab Biosimilar] (MABL-5260) | MABL-5260 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDL1/CD274 mAbs [Sugemalimab Biosimilar] (MABL-5261) | MABL-5261 | ELISA, FACS, Functional assay, in vivo binding | G4, Lambda |
| Anti-HAVCR2/TIM3 mAbs [Sabatolimab Biosimilar] (MABL-5201) | MABL-5201 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-PDCD1/CD279/PD1;HAVCR2/TIM3 mAbs [Sabestomig Biosimilar] (MABL-5202) | MABL-5202 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Lambda |
| Anti-APP mAbs [Sabirnetug Biosimilar] (MABL-5203) | MABL-5203 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-TACSTD2/TROP2/EGP1 mAbs [Sacituzumab Biosimilar] (MABL-5204) | MABL-5204 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IAP/CD47;PDL1/CD274 mAbs [Safimestomig Biosimilar] (MABL-5205) | MABL-5205 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-MOX2/CD200 mAbs [Samalizumab Biosimilar] (MABL-5206) | MABL-5206 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-F3/CD142 mAbs [Samatatug Biosimilar] (MABL-5207) | MABL-5207 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-LRRC15 mAbs [Samrotamab Biosimilar] (MABL-5208) | MABL-5208 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL6R/CD126 mAbs [Sarilumab Biosimilar] (MABL-5209) | MABL-5209 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
联系我们
Copyright © 2012-2029 西安迈博睿（Mabioway）生物科技有限公司 版权所有
地址：陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话：15339069646 邮箱：info@mabioway.cn